ArticleJournal of cellular and molecular medicine2026
RETRACTION: PEDF and 34-mer Peptide Inhibit Cardiac Microvascular Endothelial Cell Ferroptosis via Nrf2/HO-1 Signalling in Myocardial Ischemia-Reperfusion Injury.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction of
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
retractionP. Lu, Y. Qi, X. Li, C. Zhang, Z. Chen, Z. Shen, J. Liang, H. Zhang, and Y. Yuan, "PEDF and 34-mer Peptide Inhibit Cardiac Microvascular Endothelial Cell Ferroptosis via Nrf2/HO-1 Signalling in Myocardial Ischemia-Reperfusion Injury," Journal of Cellular and Molecular Medicine 28, no. 14 (2024): e18558. https://doi.org/10.1111/jcmm.18558. The above article, published online on 24 July 2024 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors; the journal Editor-in-Chief, Stefan Constantinescu; and John Wiley & Sons Ltd. A third party reported on PubPeer [1] that the majority of images in Figure 4D contained overlapping sections and that the HR+Fe-citrate(III)+PEDF images had been duplicated between Figures 4D and 5A. All affected images represent different experimental conditions. The authors responded to an inquiry by the publisher. However, the corrected data supplied by the authors could not be verified as having been derived from the original experiments. The retraction has been agreed to because the evidence of image overlap and duplication fundamentally compromises the editors' confidence in the results presented.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.